Kiora Pharmaceuticals (KPRX) Income from Non-Controlling Interests (2014 - 2026)
Kiora Pharmaceuticals' (KPRX) quarterly Income from Non-Controlling Interests came in at -$8353.0 in Q1 2026, up 48.11% YoY from -$5639.5 in Q1 2025, and down 105.13% on a QoQ basis from -$4072.0 in Q4 2025.
Kiora Pharmaceuticals (KPRX) Income from Non-Controlling Interests (2014 - 2026) Analysis & Trends
Kiora Pharmaceuticals (KPRX) has 6 years of Income from Non-Controlling Interests data on file, last reported at -$8353.0 in Q1 2026.
- Quarterly Income from Non-Controlling Interests rose 48.11% year-over-year to -$8353.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$12327.0 (down 190.51% YoY) and the FY2025 annual result came in at -$20073.0, down 167.54% from the prior year.
- Income from Non-Controlling Interests fell to -$8353.0 in Q1 2026, from -$4072.0 in the prior quarter.
- In the past five years, Income from Non-Controlling Interests ranged from a high of $76435.0 in Q3 2024 to a low of -$43888.0 in Q4 2024.
- A 3-year average of $161.62 and a median of -$6212.5 in 2025 frame the typical range for Income from Non-Controlling Interests.
- The widest YoY moves for Income from Non-Controlling Interests: up 90.72% in 2025, down 293.07% in 2025.
- Tracing KPRX's Income from Non-Controlling Interests over 3 years: stood at -$43888.0 in 2024, then jumped by 90.72% to -$4072.0 in 2025, then tumbled by 105.13% to -$8353.0 in 2026.
- The last three Income from Non-Controlling Interests figures came in at -$8353.0 (Q1 2026), -$4072.0 (Q4 2025), and $11214.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Kiora Pharmaceuticals | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10,983.00 |
| Mar 31, 2026 | -8,353.00 |
| Dec 31, 2025 | -4,072.00 |
| Sep 30, 2025 | 11,214.00 |
| Jun 30, 2025 | -11,116.00 |
| Mar 31, 2025 | -16,099.00 |
| Dec 31, 2024 | -43,888.00 |
| Sep 30, 2024 | 76,435.00 |
| Jun 30, 2024 | -2,828.00 |
| Dec 31, 2016 | -1.51 |
| Dec 31, 2015 | 5,177.00 |
| Mar 31, 2015 | 32,967.00 |
| Dec 31, 2014 | 278,123.00 |
| Sep 30, 2014 | 40,666.00 |
| Jun 30, 2014 | 58,314.00 |
| Mar 31, 2014 | 58,948.00 |